FIRVANQ KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FIRVANQ KIT (FIRVANQ KIT).
Vancomycin is a tricyclic glycopeptide antibiotic that inhibits cell wall synthesis in susceptible bacteria by binding with high affinity to the D-alanyl-D-alanine terminus of cell wall precursor units, thereby blocking peptidoglycan polymerization and cross-linking.
| Metabolism | Vancomycin is not significantly metabolized; it is excreted primarily unchanged in the urine via glomerular filtration. Less than 5% of an oral dose is absorbed systemically. |
| Excretion | Renal: >90% excreted unchanged in urine via glomerular filtration; biliary/fecal: <5%. |
| Half-life | Terminal elimination half-life: 4-6 hours in adults with normal renal function; prolonged to 7-10 days in anuric patients. Clinical context: Requires dose adjustment based on renal function. |
| Protein binding | 50-60% bound to serum proteins (primarily albumin). |
| Volume of Distribution | 0.4-1.0 L/kg (0.7 L/kg average); increased in critically ill patients. Clinical meaning: Moderate distribution, primarily extracellular; does not penetrate CSF well without inflammation. |
| Bioavailability | Intravenous: 100%; Oral: <5% (negligible systemic absorption). |
| Onset of Action | Intravenous: Immediate (within minutes) for antimicrobial effect; Oral: Not absorbed systemically; local effect in GI tract. Onset of systemic effect for C. difficile not applicable via oral route. |
| Duration of Action | Intravenous: 6-12 hours depending on renal function; Oral: Local effect persists during colonic transit. Clinical notes: Duration correlates with serum levels; monitoring trough concentrations recommended. |
| Molecular Weight | 1449.25 |
IV: 500 mg to 2 g every 8-12 hours (adjusted to target trough 15-20 mcg/mL for serious infections). Oral: 125 mg every 6 hours for 10-14 days (C. difficile).
| Dosage form | FOR SOLUTION |
| Renal impairment | CrCl >50: usual dosing; CrCl 20-49: 500 mg-1 g every 12 hours; CrCl 10-19: 500 mg-1 g every 24-48 hours; CrCl <10: 500 mg-1 g every 72-96 hours; intermittent hemodialysis: 500 mg-1 g every 48-72 hours. |
| Liver impairment | No specific Child-Pugh adjustments; vancomycin pharmacokinetics not significantly altered by hepatic impairment. |
| Pediatric use | IV: 15-20 mg/kg/dose every 6-8 hours (every 12 hours in neonates). Oral: 40 mg/kg/day divided every 6-8 hours for C. difficile. |
| Geriatric use | Dose adjustment based on renal function; monitor trough levels; consider age-related reduced GFR; usual initial dose 500 mg-1 g every 12 hours with subsequent adjustments. |
| 1st trimester | Vancomycin is considered pregnancy category B1 (Australia). Animal studies have not shown teratogenic effects, but there are limited human data. It is recommended for use only when clearly needed and when safer alternatives are ineffective or contraindicated. |
| 2nd trimester | No evidence of teratogenicity in animal studies. Vancomycin does not appear to be associated with increased risk of major birth defects based on limited human data. |
| 3rd trimester | No known fetal adverse effects. Vancomycin crosses the placenta; however, no specific risks have been identified in the third trimester. Monitor for maternal ototoxicity and nephrotoxicity. |
Clinical note
Comprehensive clinical and safety monograph for FIRVANQ KIT (FIRVANQ KIT).
| Placental transfer | Vancomycin crosses the placenta; it reaches fetal serum concentrations approximately 30-60% of maternal levels. It is not known to be teratogenic but should be used during pregnancy only if clearly needed. |
| Breastfeeding |
■ FDA Black Box Warning
Not applicable for oral vancomycin (FIRVANQ KIT is an oral solution). However, intravenous vancomycin has a black box warning for nephrotoxicity and ototoxicity, but this does not apply to the oral formulation due to minimal systemic absorption.
| Serious Effects |
Hypersensitivity to vancomycin or any component of the formulation
| Precautions | Oral vancomycin should be used with caution in patients with inflammatory disorders of the intestinal mucosa due to potential for increased systemic absorption. Monitor renal function in patients receiving prolonged therapy or with renal impairment. Prolonged use may result in superinfection with non-susceptible organisms. Consider the risk of Clostridioides difficile infection relapse. |
| Food/Dietary | No significant food interactions. However, high-fat meals may delay absorption but not clinically relevant. Avoid alcohol due to potential disulfiram-like reaction. |
Loading safety data…
| Vancomycin is poorly absorbed orally, thus infant exposure via breast milk is expected to be low. The amount ingested is unlikely to cause adverse effects in a nursing infant. However, caution is advised due to potential alteration of gut flora and risk of diarrhea. It is considered compatible with breastfeeding by most authorities. |
| Lactation Rating | L2 (Probably Compatible) |
| Teratogenic Risk | Vancomycin (FIRVANQ KIT) is generally considered low risk during pregnancy. It crosses the placenta but does not demonstrate teratogenicity in animal studies. Limited human data show no increased risk of major birth defects. However, intravenous administration in the first trimester should be reserved for cases where clearly needed. In the second and third trimesters, use is generally considered safe for maternal indications, though monitoring for maternal ototoxicity and nephrotoxicity is warranted. No specific fetal risks are consistently reported. |
| Fetal Monitoring | Maternal monitoring includes serum vancomycin trough levels to maintain therapeutic levels (typically 10-20 mcg/mL for most indications) and to avoid toxicity. Renal function (serum creatinine) and hearing (audiometry) should be assessed periodically due to potential nephrotoxicity and ototoxicity. In pregnancy, monitor for maternal hypotension during infusion. Fetal monitoring includes standard obstetrical assessments; no additional fetal monitoring specifically indicated. |
| Fertility Effects | No adverse effects on fertility have been reported in animal studies or human data for vancomycin. It does not impact sperm or oocyte function or reproductive hormones at therapeutic doses. Available evidence suggests no impact on fertility. |
| Clinical Pearls | FIRVANQ (vancomycin) is an oral formulation used for C. difficile infection. Maintain trough levels 10-20 mg/L for systemic absorption monitoring; however, oral vancomycin is minimally absorbed. Monitor renal function, especially in elderly or renally impaired patients. Do not use for empiric treatment of non-C. difficile diarrhea. |
| Patient Advice | Take oral vancomycin exactly as prescribed, every 6 hours. · Complete the full course even if symptoms improve. · Do not use for self-treatment of diarrhea. · Report signs of allergic reaction or severe diarrhea worsening. · Avoid alcohol consumption during treatment (may cause disulfiram-like reaction). · Store at room temperature away from moisture. |